EyePoint, Inc. (EYPT) SEC Filings & Earnings Calls

Clinical trial outcome unknown; potential for failure or success not yet disclosed.

“No efficacy or safety data provided in excerpt.”

Clinical trial failure in wet AMD leads to pipeline uncertainty and cash burn risk

“Phase 3 LUCIA study did not meet primary endpoint; company pivots to DME program with readout in Q4 2027”

Workforce reduction may impair operational execution and morale

“53% workforce reduction; substantial majority in Q4 2026”

Clinical trial results not disclosed in excerpt; outcome unknown.

“Topline data announced but not detailed in the provided excerpt.”

Clinical trial risk: Phase 3 data readouts for wet AMD and DME are binary events.

“Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026” · word for word

Revenue decline due to YUTIQ license deferred revenue recognition ending.

“The decrease was primarily driven by the recognition of remaining deferred revenue related to the Company’s 2023 agreement for the license of YUTIQ ® product rights.” · word for word

DOJ Settlement and Corporate Integrity Agreement

“the Company agreed, among other things, to pay a settlement amount of $4,678,981.86, plus interest at a rate of 4.25% per annum from January 28, 2026”

Litigation with Ocular Therapeutix

“On March 20, 2026, we filed a complaint (the “Complaint”) against Ocular Therapeutix, Inc. (“Ocular”) in the Middlesex County Superior Court for the Commonwealth of Massachusetts” · word for word

No product revenue; reliance on partnership and financing

“The Company has a history of operating losses and has not had significant recurring cash inflows from revenue.” · word for word

Cash runway limited to Q4 2027

“We expect that our cash and investments in marketable securities will enable us to fund our operations into the fourth quarter of 2027.” · word for word

FDA Warning Letter for YUTIQ manufacturing

“the Warning Letter we received from the FDA in July 2024, or the Warning Letter, pertaining to YUTIQ ® manufacturing” · word for word

Clinical trial failure risk remains; positive results not yet reported.

“Phase 3 trials are ongoing; no efficacy or safety data disclosed.”

Litigation liability resolved but compliance risk remains; Corporate Integrity Agreement imposes ongoing obligations and potential penalties for non-compliance.

“Corporate Integrity Agreement for 5 years; failure to comply could result in monetary penalties or exclusion from federal healthcare programs.”

Potential dilution from increased share authorization under LTIP.

“increase the number of shares of Common Stock authorized for issuance thereunder by 4,900,000 shares.” · word for word

Clinical trial risk remains; positive DSMC is encouraging but not final approval.

“Phase 3 program still ongoing; DSMC recommendation is interim.”

Litigation liability pressure

“On March 20, 2026, we filed a complaint against Ocular Therapeutix, Inc. ... The complaint alleges, among other things, Ocular’s dissemination of false or misleading representations of fact concerning our company and the clinical results of DURAVYU.” · word for word

Regulatory compliance cost

“Our expectations regarding an agreement in principle with the U.S. Attorneys’ Office for the District of Massachusetts (DOJ) and the Office of the Inspector General of the Department of Health and Human Services related to the DOJ’s investigation into certain of our sales, marketing and promotional practices as pertain to DEXYCU.” · word for word

Clinical trial failure risk; revenue decline due to deferred revenue recognition; cash burn rate.

Clinical trial failure risk

“the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available” · word for word

Regulatory approval uncertainty

“uncertainties and delays relating to communications with the U.S. Food and Drug Administration and the ability to obtain regulatory approval from FDA for the commercialization of DURAVYU” · word for word

Manufacturing facility risk

“uncertainties regarding the FDA warning letter pertaining to the Company’s Watertown, MA manufacturing facility” · word for word

DOJ investigation risk

“our ability to enter into a settlement agreement and corporate integrity agreement with the government regarding the DOJ investigation and uncertainties related to the impact such agreements would have on our business, financial condition and results of operations” · word for word

No material risk identified.

Litigation liability pressure from defamation lawsuit; potential reputational damage and legal costs.

“Lawsuit filed against Ocular Therapeutix for false statements about DURAVYU; seeks monetary damages.”

Clinical trial failure risk

“DURAVYU is currently in Phase 3 clinical trials for the potential treatment of wet AMD and DME... Enrollment in the pivotal Phase 3 clinical trials for wet AMD is complete with data expected beginning in mid-2026.” · word for word

Regulatory and legal risk from DOJ investigation

“In the first quarter of 2026, we reached an agreement in principle with the DOJ to settle matters related to the DOJ investigation into certain of our sales, marketing and promotional practices as pertain to DEXYCU during the period for which we commercialized this product.” · word for word

Dependence on single product candidate

“Our lead product candidate, DURAVYU... is currently being evaluated in Phase 3 pivotal trials (LUGANO and LUCIA) for wet AMD and in Phase 3 clinical trials (COMO and CAPRI) for DME.”

Cybersecurity and data privacy risk

“Despite the implementation of security measures, our internal computer systems and those of third parties with which we interact, including our contractors and consultants, are vulnerable to unauthorized access.” · word for word

Clinical trial risk; no approved products; reliance on DURAVYU success.

“Phase 3 data readouts not until mid-2026; no revenue from approved products.”

Clinical trial risk; no approved products; reliance on DURAVYU success.

“Phase 3 trials for DME; data expected H2 2027.”

Clinical trial risk: Phase 3 data readouts are pending; failure could impair pipeline value.

“Topline data from Phase 3 wet AMD program anticipated beginning in mid-2026; DME program first patient dosing expected Q1 2026.”

DOJ investigation and potential settlement

“The Company believes it will incur an expense in connection with the possible settlement of the DOJ’s investigation of approximately $4.7 million, plus additional legal expense.” · word for word

Clinical trial execution risk

“DURAVYU™ is currently being evaluated in Phase 3 pivotal trials (LUGANO and LUCIA) for wet age-related macular degeneration (wet AMD) with data readout beginning in mid-2026.” · word for word

Reliance on future capital raises

“The Company expects to continue fulfilling its funding needs through cash inflows from licensing and research collaboration transactions, additional equity capital raises and other arrangements.” · word for word

Dilution risk from equity offering

“Offering of up to $200M of common stock via ATM program.”

Potential cash burn or need for capital

“Company raising capital through equity offering; no specific use of proceeds stated.”

Significant operating losses and cash burn; net loss increased to $59.7M from $29.4M YoY.

“net loss was $59.7 million, or ($0.85) per share, compared to a net loss of $29.4 million” · word for word

Dependence on DURAVYU clinical trial success; no approved products generating significant revenue.

“Phase 3 LUGANO and LUCIA clinical trials for DURAVYU in wet AMD fully enrolled and on track for data readout beginning in mid-2026” · word for word